Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Polyus' Board of Directors proposed a share split

12/24/24 PLZL

Fix Price has registered a Russian legal entity

12/24/24 FIXP

Trading in shares of "Corporate Center X 5" will begin on January 9

12/24/24 X5

Nizhnekamskneftekhim completed construction of EP-600

12/24/24 NKNC

MTS subsidiary will be given 10 billion rubles to create mobile base stations

12/24/24 MTSS

Shareholders of Novoship approved dividends

12/24/24 NOMP

Rostelecom acquires 37.5% of First Data

12/23/24 RTKM

Konstantin Strukov will repay ₽22.9 billion of debt guaranteed by UGC

12/23/24 UGLD

Etalon Group launched sales in MariInn Park residential complex

12/23/24 ETLN

Shadow LNG fleet resumes operations after months of hiatus

12/23/24 NVTK